Drug intelligence / Profile preview

Anivina

Development stage: Unknown
Lead developer: Nguyen Van Toan
Modality: Small Molecules

Overview

**Anivina** is an investigational composition of naturally occurring bioactive compounds evaluated for type 2 diabetes mellitus with associated gastrointestinal and splenic dysfunction. A registered Phase 3 study led by Nguyen Van Toan assessed whether the product could improve splenic and gastrointestinal tract function in people with type 2 diabetes mellitus. Its individual active constituents, formulation, route of administration, molecular targets, and specific pharmacologic mechanism have not been publicly disclosed.

Other names: Anivina

Beyond the preview

Go deeper on Anivina.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Anivina.

Explore the full profile